Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease

Massimiliano Runfola, Michele Perni, Xiaoting Yang, Maria Marchese, Andrea Bacci, Serena Mero, Filippo M. Santorelli, Beatrice Polini, Grazia Chiellini, Daniela Giuliani, Antonietta Vilella, Martina Bodria, Eleonora Daini, Eleonora Vandini, Simon A. Rudge, Sheraz Gul, Michale O. J. Wakelam, Michele Vendruscolo, Simona RapposelliPharmaceuticals 2021 · DOI

TL;DR

Researchers have developed a novel thyroid hormone derivative, SG2, that shows promise as a multi-target therapeutic for Alzheimer's disease (AD). SG2 demonstrates a pleiotropic effect, promoting autophagy, neuroprotection, and metabolic reprogramming, and has shown efficacy in both worm and mouse models of AD with low toxicity.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide, characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. Current therapeutic approaches have limited success, highlighting the need for novel strategies that can address the complex, multi-faceted nature of AD pathogenesis. The authors propose that a "polypharmacological" approach, where a single compound targets multiple pathways involved in AD, could be a more effective strategy. They aim to identify and characterize such a compound, focusing on derivatives of thyroid hormones, which are known to influence various cellular processes relevant to AD, including protein homeostasis, neurodevelopment, and metabolism.

Methods

The study employed a multidisciplinary approach, combining in vitro assays, in vivo models, and toxicological profiling:

  • C. elegans Model: A genetically modified C. elegans strain expressing human Aβ42 was used to assess SG2's effect on lifespan and motility. This model is standard for initial drug screening in AD research.
  • In Vitro Aβ Aggregation Assays: Thioflavin T (ThT) fluorescence assays were used to monitor the aggregation of Aβ42 in the presence and absence of SG2, with and without preformed fibrils (seeds), to understand SG2's direct impact on Aβ aggregation.
  • Autophagy Assays in C. elegans: A C. elegans strain expressing GFP-tagged LGG-1 (an autophagy marker) was used to assess SG2's ability to induce autophagy, a key cellular process implicated in clearing misfolded proteins.
  • Cell-Based Neurotoxicity Assays: U87MG human glioblastoma cells were used to evaluate SG2's protective effects against Aβ25-35-induced toxicity and its impact on autophagy-related gene expression (mTOR, σ1R, SIRT1, SIRT6).
  • In Vitro ADME-Tox Profiling: A panel of assays was used to assess SG2's cytotoxicity and potential off-target effects on epigenetic modulators (HDACs, sirtuins) and specific kinases.
  • In Vivo Zebrafish Toxicity Studies: Zebrafish embryos and larvae were used to evaluate SG2's safety profile, assessing mortality, morphological development, cardiotoxicity, and neurological development.
  • 5XFAD Mouse Model: Young 5XFAD mice, a well-established model for AD, were used to assess SG2's effects on spatial learning and memory using the Morris Water Maze (MWM) task.

Datasets

Not explicitly discussed as datasets in the context of machine learning. The study utilizes established biological models and experimental readouts.

Key Insights and Ideas

  • Thyroid Hormone Derivatives as Polypharmacological Agents: The study highlights the potential of thyroid hormone derivatives, like SG2, to act as multi-target agents for complex diseases like AD, addressing multiple pathological pathways simultaneously.
  • SG2's Pleiotropic Effects: SG2 demonstrates a range of beneficial effects beyond simply targeting Aβ aggregation, including promoting autophagy, neuroprotection, and improving cognitive function. This "pleiotropic" nature is key to its potential as a broad-acting therapeutic.
  • Autophagy as a Key Mechanism: The findings strongly suggest that SG2's therapeutic effects are mediated, at least in part, by the activation of the autophagy-lysosomal pathway, which is crucial for clearing toxic protein aggregates in AD.
  • Low Toxicity Profile: A significant finding is SG2's favorable safety profile, demonstrated across multiple models (in vitro cell lines, zebrafish), suggesting a good therapeutic window.

Key Results

  • C. elegans: SG2 treatment significantly improved motility and extended lifespan in a C. elegans model of AD, even when administered late in the disease progression.
  • Aβ Aggregation: SG2 did not directly inhibit Aβ42 aggregation in vitro but showed a mild effect on accelerating primary nucleation in unseeded assays. Its beneficial effects in vivo are therefore likely due to other mechanisms.
  • Autophagy: SG2 significantly enhanced autophagy in C. elegans models of AD, as evidenced by increased LGG-1::GFP foci.
  • Cellular Neuroprotection: SG2 protected U87MG cells from Aβ25-35-induced toxicity and reversed the Aβ-induced dysregulation of autophagy-related genes (mTOR, σ1R, SIRT1, SIRT6).
  • Safety: SG2 exhibited low cytotoxicity in various human cell lines and demonstrated no significant adverse effects on zebrafish embryonic development at efficacious concentrations.
  • Mouse Model: In 5XFAD mice, SG2 treatment led to improved spatial learning and memory, as indicated by a higher learning index and a greater use of spatial strategies in the Morris Water Maze.

Limitations and Future Work

  • Mechanism of Action: While SG2's effects on autophagy are evident, the precise molecular targets and downstream mechanisms responsible for its pleiotropic actions remain to be fully elucidated. The authors state that further studies are required to clarify these biological mechanisms.
  • Early Stage of AD: The study primarily focused on the early stages of AD pathology in the 5XFAD mouse model. Future work should investigate SG2's efficacy in older mice with more advanced disease progression, including its potential to reduce Aβ-induced neuroinflammation.
  • Clinical Translation: The current work represents a preclinical investigation. Further research, including medicinal chemistry optimization and extensive in vivo studies, will be necessary to translate these findings into a potential human therapeutic. The authors are actively engaged in a medicinal chemistry program to address target deconvolution and hit-to-lead optimization.

Summary updated

Abstract

The identification of effective pharmacological tools for Alzheimer's disease (AD) represents one of the main challenges for therapeutic discovery. Due to the variety of pathological processes associated with AD, a promising route for pharmacological intervention involves the development of new chemical entities that can restore cellular homeostasis. To investigate this strategy, we designed and synthetized SG2, a compound related to the thyroid hormone thyroxine, that shares a pleiotropic activity with its endogenous parent compound, including autophagic flux promotion, neuroprotection, and metabolic reprogramming. We demonstrate herein that SG2 acts in a pleiotropic manner to induce recovery in a <i>C. elegans</i> model of AD based on the overexpression of Aβ42 and improves learning abilities in the 5XFAD mouse model of AD. Further, in vitro ADME-Tox profiling and toxicological studies in zebrafish confirmed the low toxicity of this compound, which represents a chemical starting point for AD drug development.
BibTeX
@inproceedings{runfola2021identification,
  author = {Massimiliano Runfola and Michele Perni and Xiaoting Yang and Maria Marchese and Andrea Bacci and Serena Mero and Filippo M. Santorelli and Beatrice Polini and Grazia Chiellini and Daniela Giuliani and Antonietta Vilella and Martina Bodria and Eleonora Daini and Eleonora Vandini and Simon A. Rudge and Sheraz Gul and Michale O. J. Wakelam and Michele Vendruscolo and Simona Rapposelli},
  title = {{Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease}},
  booktitle = {Pharmaceuticals},
  year = {2021},
  doi = {10.3390/ph14121330},
}
Figure